Fig. 3
Opportunities for minimal residual disease assessment to complement clinical management. Numbers represent scientific question that are being explored by trials summarized in Table 2
Fig. 3 | Molecular Cancer
Opportunities for minimal residual disease assessment to complement clinical management. Numbers represent scientific question that are being explored by trials summarized in Table 2
Molecular Cancer